Provided by Tiger Trade Technology Pte. Ltd.

Legend Biotech

17.58
+0.58003.41%
Post-market: 17.720.1400+0.80%18:02 EDT
Volume:1.95M
Turnover:34.35M
Market Cap:3.42B
PE:-35.11
High:17.85
Open:17.38
Low:17.30
Close:17.00
52wk High:37.50
52wk Low:16.24
Shares:194.49M
Float Shares:91.34M
Volume Ratio:0.60
T/O Rate:2.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5008
EPS(LYR):-1.6200
ROE:-8.08%
ROA:-1.92%
PB:2.78
PE(LYR):-10.85

Loading ...

Genscript Highlights Legend Biotech’s New CAR-T Data in Oncology Programs

TIPRANKS
·
Jun 01

Legend Points Carvykti Toward Use in Earlier Setting, RBC Says

MT Newswires Live
·
Jun 01

Legend Biotech Showcases First-in-Human LB2102 Data and Strengthens CARVYKTI Profile at ASCO 2026

TIPRANKS
·
Jun 01

Legend Biotech says Phase 1 LB2102 CAR-T posts 28.6% response rate in relapsed solid tumors at higher doses

Reuters
·
Jun 01

Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026

GlobeNewswire
·
Jun 01

Oppenheimer Remains a Buy on Legend Biotech (LEGN)

TIPRANKS
·
Jun 01

J&J Mastered Cancer Biotech Deals on the Cheap. Can it Stay on the Cutting Edge? -- Heard on the Street -- WSJ

Dow Jones
·
May 28

GENSCRIPT BIO Surges Over 5% Following Partner Legend Biotech's ASCO 2026 Research Presentations

Stock News
·
May 27

A Look At Legend Biotech (LEGN) Valuation After Its Strong Q1 2026 Revenue And Narrower Net Loss

Simply Wall St.
·
May 22

Legend Biotech to Showcase New CAR-T Data at ASCO 2026

TIPRANKS
·
May 22

Legend Biotech presents preliminary Phase 1 LB2102 data in small-cell lung cancer at ASCO 2026

Reuters
·
May 22

Legend Biotech Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
May 18

Analysts Are Bullish on Top Healthcare Stocks: Legend Biotech (LEGN), Krystal Biotech (KRYS)

TIPRANKS
·
May 18

HHLR's Q1 Portfolio: Capital Flows to Semiconductor Sector, PDD and Alibaba Remain Top Holdings

Stock News
·
May 16

These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results

Benzinga Earnings
·
May 14

Legend Biotech price target lowered to $48 from $49 at Morgan Stanley

TIPRANKS
·
May 14

Legend Biotech Is Maintained at Outperform by RBC Capital

Dow Jones
·
May 13

Legend Biotech Q1 Solid for Carvykti, Focus Shifts to In Vivo Pipeline, RBC Says

MT Newswires Live
·
May 13

Legend Biotech price target raised to $64 from $62 at RBC Capital

TIPRANKS
·
May 13

RBC Lifts Price Target on Legend Biotech to $64 From $62, Keeps Outperform Rating

MT Newswires Live
·
May 13